{"id":"b007","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hyperglycemia"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4464151","moleculeType":"Unknown","molecularWeight":"530.50"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"B007 works by inhibiting the activity of PI3K, a key enzyme in the PI3K/AKT signaling pathway, which is involved in cell proliferation and survival. This inhibition leads to a decrease in AKT activity, resulting in anti-tumor effects.","oneSentence":"B007 is a small molecule that targets the PI3K/AKT signaling pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:57:45.413Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors with PI3K/AKT pathway alterations"}]},"trialDetails":[{"nctId":"NCT06470191","phase":"PHASE2, PHASE3","title":"A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.","status":"RECRUITING","sponsor":"Shanghai Jiaolian Drug Research and Development Co., Ltd","startDate":"2024-07-30","conditions":"Primary Membranous Nephropathy","enrollment":216},{"nctId":"NCT05668403","phase":"PHASE1","title":"A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy","status":"RECRUITING","sponsor":"Shanghai Jiaolian Drug Research and Development Co., Ltd","startDate":"2023-03-02","conditions":"Primary Membranous Nephropathy","enrollment":52},{"nctId":"NCT06447597","phase":"PHASE2, PHASE3","title":"A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.","status":"RECRUITING","sponsor":"Shanghai Jiaolian Drug Research and Development Co., Ltd","startDate":"2024-07-01","conditions":"Generalized Myasthenia Gravis","enrollment":104},{"nctId":"NCT06454357","phase":"PHASE2, PHASE3","title":"A Clinical Study of B007 in the Treatment of Pemphigus.","status":"RECRUITING","sponsor":"Shanghai Jiaolian Drug Research and Development Co., Ltd","startDate":"2024-07-12","conditions":"Pemphigus","enrollment":132}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"B007","genericName":"B007","companyName":"Shanghai Jiaolian Drug Research and Development Co., Ltd","companyId":"shanghai-jiaolian-drug-research-and-development-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"B007 is a small molecule that targets the PI3K/AKT signaling pathway. Used for Advanced solid tumors with PI3K/AKT pathway alterations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}